ACIU

AC Immune

• TipRanks·10/02 12:27

  AC Immune Adds Tom Graney to Board Following Extraordinary General Meeting

• NASDAQ·09/30 10:43

  Best Momentum Stock to Buy for September 30th

• NASDAQ·09/29 11:50

  Teva's Branded Drugs Take Center Stage in Its Growth Strategy

• NASDAQ·09/26 20:02

  AC Immune Parkinson’s Vaccine Study Meets Safety, Immunogenicity Goals

• Seeking Alpha·09/24 19:21

  AC Immune: Buy Continued ACI-7104 Progress, PD, And Pipeline Expansions

• TipRanks·09/24 10:25

  Fein Reiterates Buy on AC Immune as VacSYn Phase 2 Data Validate Platform; $12 Price Target Maintained

• Dow Jones·09/24 09:31

  AC Immune Price Target Maintained With a $8.00/Share by BTIG

• Benzinga·09/23 15:08

  AC Immune Says Investigational Parkinson’s Drug Shows 100% Antibody Response

• NASDAQ·09/23 12:40

  AC Immune Posts Positive Week 100 Phase 2 Data For ACI-7104 In Parkinson's Disease; Stock Up

• Seeking Alpha·09/23 11:52

  AC Immune spikes after mid-stage trial data for Parkinson’s drug

• TipRanks·09/23 11:28

  AC Immune Posts Strong Week-100 Phase 2 Data for Parkinson’s Vaccine ACI-7104

• TipRanks·09/23 11:25

  AC Immune announces Phase 2 trial of ACI-7104 met primary endpoints

• Benzinga·09/23 11:05

  AC Immune Announces Safety And Immunogenicity Results Through Week 100 In Part 1 Of VacSYn, Its Phase 2 Trial Of ACI-7104 In Patients With Early-Stage Parkinson’s Disease: All Primary Endpoints Were Met, Generally Safe And Well Tolerated; Strong Immunogenicity Demonstrated, With 100% Response Rate After Three Immunizations

• NASDAQ·09/22 16:23

  FDA Accepts Insmed's Filing Seeking Label Expansion for Arikayce

• NASDAQ·09/17 16:13

  Kiniksa Pharmaceuticals Stock Rallies 41% in Three Months: Here's Why